[Correspondence] Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer

Like Fang Wu and colleagues, we also read with great interest the ADJUVANT study,1 which showed that patients with stage II–IIIA (N1–N2) EGFR-mutant non-small-cell lung carcinoma treated with adjuvant gefitinib had significantly longer disease-free survival and fewer side-effects, than did those treated with vinorelbine plus cisplatin. However, caution should be used when choosing gefitinib as adjuvant treatment because some questions remain unanswered.

http://ift.tt/2F2C3FT